환자 유래 종양은 환자의 약물 내성을 예측하기위한 "라이브"전임상 플랫폼으로 이월합니다.

Executive Industry Relevance

Patient-derived tumor explants (PDEs) provide a clinically relevant preclinical platform that preserves the tumor microenvironment and intratumoral heterogeneity, directly addressing a major limitation of traditional models. This enables more predictive assessment of drug resistance and sensitivity, supporting translational continuity from discovery to patient stratification. The PDE platform enhances portfolio decision-making by generating actionable, quantitative drug response and biomarker data aligned with clinical outcomes.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of therapeutic hypotheses in a human tumor context.
• Supports functional target validation by preserving tumor-stroma interactions.
• Facilitates mechanistic de-risking through direct measurement of drug effects on viable tumor tissue.
• Improves predictive confidence for advancing targets into later-stage development.

Screening & Assay Development

• Provides a validated 3D biological system for compound screening under physiologically relevant conditions.
• Enables quantitative, reproducible assessment of cell viability, proliferation, and death post-treatment.
• Supports assay standardization and scalability for high-content drug evaluation.
• Allows for multiplexed biomarker analysis to inform screening prioritization.

Translational & Preclinical Research

• Aligns preclinical drug response data with clinicopathological parameters for translational biomarker discovery.
• Enables risk-adjusted advancement decisions by predicting patient-specific drug resistance or sensitivity.
• Supports identification of novel interventional strategies to sensitize resistant tumors.
• Facilitates continuity from discovery through preclinical validation using patient-relevant models.

Pipeline & Workflow Integration

PDEs integrate into the discovery-to-preclinical continuum by providing a bridge between in vitro screening and clinical translation, supporting both lead identification and biomarker-driven patient stratification.

• Discovery Biology: Supports hypothesis testing and pathway clarification in a preserved tumor microenvironment.
• Screening: Delivers reproducible, quantitative outputs for compound evaluation in a 3D context.
• Analytics: Enables high-content measurements, including spatial profiling and cell segmentation, to compare drug effects.
• Translational Research: Aligns drug response data with clinical parameters for biomarker validation.
• Enterprise Reuse: Establishes a reusable platform for ongoing drug sensitivity and resistance studies across tumor types.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in drug response assessment.
• Operational Value: Standardizes workflows for tissue processing, imaging, and quantitative analysis.
• Strategic Value: Improves go/no-go decisions and capital efficiency by linking preclinical data to patient outcomes.
• Portfolio Impact: Enables risk-adjusted prioritization and advancement of drug candidates based on clinically relevant data.

Implementation Considerations

• Requires expertise in tissue handling, histology, and advanced imaging analysis.
• Demands access to multiplexed immunofluorescence and multispectral imaging infrastructure.
• Necessitates cross-team standardization for sample processing and data interpretation.
• Adaptation may be needed for different tumor types and bespoke culture conditions.
• Short-term culture limits longitudinal studies but enables rapid drug response assessment.

Biopharma FAQs